SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the crypto market experiences volatility, sparking debates about potential bottom levels and the impact of large holders like MicroStrategy. Community discussions range from calling it a "pedo ponzi coin" to anticipating a surge to $200K, highlighting the highly polarized sentiment around its future. Investors are closely watching for key support levels and potential market corrections.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards amidst Bitcoin's recent volatility, sparking debates about its correlation with BTC and potential risks. Community discussions range from concerns about margin calls and possible delisting to speculation on a potential bottom, with some traders eyeing a bounce while others foresee further declines. The stock's performance is closely tied to Bitcoin's price movements and Michael Saylor's strategy, leading to heightened uncertainty and a wide range of opinions.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as investors discuss its correlation to Ethereum's price movements and upcoming earnings, with many expressing concerns over recent price drops and the impact of crypto market volatility. The community is actively debating the influence of figures like Tom Lee and Cathie Wood, while also pondering potential catalysts such as staking announcements and possible market manipulation. Discussions include BMNR's NAV, potential risks, and the overall sentiment surrounding crypto investments.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending following earnings, with community members pointing to strong revenue growth and a significant EPS beat. Despite positive results, some express concern about the overall market conditions and potential dilution, while others remain bullish, anticipating future upgrades and a rise in stock price. Discussions also revolve around institutional interest and comparisons to similar companies like Robinhood.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid volatility, with investors reacting to a UBS price target increase and broader market concerns. Community discussions revolve around whether the recent selloff presents a buying opportunity or signals an overbought condition, especially with Nvidia's earnings on the horizon. Sentiment is mixed as some anticipate a continued rally driven by AI memory demand, while others foresee a deeper correction.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB is trending as a novel token on the ICP blockchain, drawing comparisons to an early-stage Bitcoin due to its limited supply and halving schedule, sparking community interest. Discussions revolve around its potential for significant growth, particularly in relation to the ICP ecosystem, with some viewing it as a way to support the network. The community is closely watching upcoming halving events and their potential impact on price.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

LEU is trending due to a multi-billion dollar investment in its uranium enrichment expansion, sparking bullish sentiment. The community is discussing the potential for a short squeeze given the high short interest and small float. Broader context includes rising interest in nuclear energy, driven by AI and national security concerns.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

HOOD is trending amidst a recent dip, sparking debates about oversold conditions and potential for a rebound. Community members are weighing bullish and bearish scenarios, influenced by factors like Bitcoin's performance and broader market trends. Some traders discuss strategies like buying the dip or selling covered calls, while others speculate on future price movements and potential impacts of upcoming economic data.

SSgA Active Trust - SPDR S&P 500 ETF Trust

Amidst market volatility, the SPY is trending as investors debate whether recent declines signal a larger correction or a temporary pullback. Community discussion revolves around potential triggers, including concerns about AI valuations, the Federal Reserve's next moves, and the impact of a crypto sell-off, with some anticipating a bounce while others brace for further downside.

ETF Opportunities Trust - T-REX 2X Long BMNR Daily Target ETF

T-REX 2X Long BMNR Daily Target ETF

The T-REX 2X Long BMNR Daily Target ETF ($BMNU) is trending as traders discuss its potential for gains amidst fluctuations in Ethereum ($ETH) and its underlying asset, Bit Mining ($BMNR). Community chatter revolves around the ETF's leveraged exposure, with some expressing concerns about potential reverse splits and others anticipating a significant rally if Ethereum rebounds. The conversation also highlights the debate around its tracking accuracy and suitability for short-term trading.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells 15,000 Shares of Stock

Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Dongfang Liu sold 15,000 shares of Nuvation Bio stock in a transaction dated Monday, November 17th. The stock was sold at an average price of...

Nuvation Bio Target of Unusually High Options Trading (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) was the target of some unusual options trading activity on Wednesday. Investors bought 11,651 call options on the stock. This represents an increase of...

<ul class="summary-bullets"><li>Shares jumped after Wedbush raised its target and B. Riley initiated coverage, pointing to strong early launch momentum for the new lung-cancer therapy.</li><li>The company reported 204 first-quarter patient starts and outlined revenue potential between $220 million and $2 billion.</li><li>Fresh glioma data, upcoming ex-U.S. partnership plans, and an expected Phase I/II update added to investor enthusiasm.</li></ul><p>Nuvation Bio, Inc. logged its best trading session on record after a wave of bullish analyst updates tied to the first full-quarter results for its newly launched ROS1 lung-cancer therapy. The stock jump followed new commentary from the company during its appearance at the Jefferies London Healthcare Conference 2025, prompting multiple brokerages to boost their outlook.</p><p>The stock closed up 49% at $7.15, hitting nearly a four-year high, and added another 1.4% in after-hours trading.</p><h2 class="st-heading-2"><strong>Analysts Turn Bullish</strong></h2><p>Wedbush raised its price target to $11 from $7 and reiterated an ‘Outperform’ rating.<br>Meanwhile, B. Riley initiated coverage with a ‘Buy’ rating and a $12 price target, highlighting the company’s strong early commercial revenue ramp in mutation-defined lung cancer. The firm said the therapy’s launch is being supported by what it described as “class-leading attributes” that continue to underpin robust early metrics.</p><h2 class="st-heading-2"><strong>New Lung Cancer Therapy</strong></h2><p>During the conference, Nuvation said its first full quarter of sales for its ROS1 inhibitor resulted in 204 new patient starts, six times the number logged by its closest competitor in its comparable launch period. The company reported a 90% response rate and a 50-month duration of response in updated data already submitted for a label amendment.</p><p>The company said that even without additional growth, the current quarterly intake alone could support annual revenue ranging from $220 million to $2 billion, depending on the mix of first-line and second-line patients. Access has expanded to more than 80% of covered lives, with minimal need for fast-start support programs.</p><h2 class="st-heading-2"><strong>New Glioma Data</strong></h2><p>Investors also reacted to new data for the company’s IDH1 inhibitor, which showed a 44% response rate in low-grade glioma, marking four times that of the INDIGO study’s comparator, and an 88% two-year progression-free rate. Nuvation Bio said its program covering both low-grade and high-grade glioma is underway and expected to read out by 2029.</p><p>The company said it no longer plans a head-to-head comparison study, citing the strength and separation of the newly disclosed data.</p><h2 class="st-heading-2"><strong>The Path Ahead</strong></h2><p>Nuvation said its adjuvant study for ROS1 lung cancer is progressing and will run for several years. An ex-U.S. commercial partnership is expected before year-end, ahead of commercial ramp-ups in China and Japan.</p><p>The company reported $549 million in cash at the end of the last quarter and maintained that its balance sheet is sufficient to take it through to profitability. The Phase I/II trial of its NUV-1511 drug-drug conjugation program remains ongoing, with updates due before the end of the year.</p><h2 class="st-heading-2"><strong>Stocktwits Mood Turns Upbeat</strong></h2><p>On Stocktwits, retail sentiment for Nuvation Bio was ‘extremely bullish’ amid a 1,538% surge in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:954/137;" src="https://news.stocktwits-cdn.com/nuvb_ss_png_b7b070e23e.webp" alt="nuvb ss.png" width="954" height="137"><figcaption>NUVB sentiment and message volume as of November 21 | Source: Stocktwits</figcaption></figure><p>One user said, “buying 2000 more shares at this level,” while another said, “The fact that it's doing so well on a red day is amazing!”</p><p><stembedurl>https://stocktwits.com/GTMStox/message/636798062</stembedurl></p><p><stembedurl>https://stocktwits.com/GTMStox/message/636786236</stembedurl></p><p><a href="https://stocktwits.com/symbol/NUVB">Nuvation Bio’s stock</a> has risen 49% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Nuvation Bio’s stock (NUVB) has risen 49% so far in 2025. (Photo credit: Getty Images)

Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut 

Shares jumped after Wedbush raised its target and B. Riley initiated coverage, pointing to strong early launch momentum for the new lung-cancer therapy.

Equity

Los Angeles Capital Management LLC Buys Shares of 106,020 Nuvation Bio Inc. $NUVB

Los Angeles Capital Management LLC bought a new position in Nuvation Bio Inc. (NYSE:NUVB - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange...

Nuvation Bio (NYSE:NUVB) Trading Up 9.6% - Should You Buy?

Nuvation Bio (NYSE:NUVB) Shares Up 9.6% - What's Next...

Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Rating of "Moderate Buy" by Brokerages

Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) has been given an average rating of "Moderate Buy" by the nine analysts that are presently covering the company, Marketbeat.com reports. One equities...

Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates

Nuvation Bio (NUVB) delivered earnings and revenue surprises of +5.88% and +95.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended...

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief...

MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates

MiMedx (MDXG) delivered earnings and revenue surprises of +114.29% and +19.99%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Current Price	$7.01
Prev Close	$7.15
Open	$7.20
Dividend Yield	0.00%
50-Day Moving Average	$4.19
Beta	1.50
Avg. Volume	8.3M
PE Ratio	-10.95

52-Week High	$7.50
52-Week Low	$1.54
Market Capitalization	$2.46B
EPS (Annual)	-$2.11
Price to Book	7.37
Revenue Per Employee	$35,786.36
Enterprise Value/EBITDA	N/A

NUVB
Nuvation Bio Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NUVB News

NUVBNuvation Bio Inc - Ordinary Shares - Class A